 |
|
Math could help cure leukemia
June 20, 2008When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer.
In a recent study that combined math and medicine, researchers have shown that patients with chronic myelogenous leukemia (CML) may be cured of the disease with an optimally timed cancer vaccine, where the timing is determined based on their own immune response.
In the June 20 edition of the journal PLoS Computational Biology, University of Maryland associate professor of mathematics Doron Levy, Stanford Medical School physician and associate professor of medicine (hematology) Peter P. Lee, and Dr. Peter S. Kim, École Supérieure d'Électricité (Gif-sur-Yvette, France) describe their success in creating a mathematical model which predicts that anti-leukemia immune response in CML patients using the drug imatinib can be stimulated in a way that might provide a cure for the disease.
"By combining novel biological data and mathematical modeling, we found rules for designing adaptive treatments for each specific patient," said Levy, of the University of Maryland Center for Scientific Computation and Mathematical Modeling. "Give me a thousand patients and, with this mathematical model, I can give you a thousand different customized treatment plans."
Math and Leukemia
While the marriage of math and biology is only beginning to catch on in science, there have been other attempts to use equations to understand how leukemia develops and evolves over time. Levy, Lee, and Kim's study differed in that it took into account the patient's natural immune response in conjunction with the effects of imatinib, a drug that has been successful in putting CML patients into remission.
They wanted to see if they could develop a mathematical model, or set of rules, that would increase chances for long-term remission in individual patients. Over four years, Lee's laboratory collected data from CML patients, measuring the strength of each patient's immune response, in the form of the numbers and the activity of the anti-leukemia T cells, at different times during imatinib therapy.
"Our results suggest that it is not only the drug that sends the leukemia into remission, it's also the natural immune response," Levy said. "After starting imatinib, the anti-leukemia immune response gradually increases. However, it begins to weaken after it reaches a peak. This typically happens well into the treatment.
"Leukemia cells are still present, but in relatively low numbers that causes the immune response to wind down. Unfortunately, this is an ideal time for the cancer cells to develop drug resistance and render the therapy ineffective."
Best Time for Immune Response
Incorporating Lee's clinical data on immune response, Levy's model suggests that the immune response of the patients should be boosted at the time when their immune response starts weakening.
The authors suggest that such a stimulation can be provided in the form of "cancer vaccines," in which pre-therapy blood taken from patients is irradiated to kill active cancer cells, then introduced back to the patient. A strong stimulation of the immune system was shown to be active in vitro in Lee's lab experiments.
"The mathematical approach showed that it is imperative to connect the timing of the cancer vaccine with the individual profile of the immune response of each patient," Levy said. "The mathematical simulations suggest that a vaccine administered within the initial months of the treatment will have no effect on the progression of the disease. On the other hand, a well-timed vaccine can potentially cure the disease."
Individual Therapy Plan
But the dynamics of each patient's immune response differ. That's where the math comes in, says Levy. "We can find rules for application to a specific patient. We can measure each patient's parameters to find when the dosage will be most effective. Mathematics provides the tools that are necessary to tailor the treatment to the patient."
"While some parameters can be measured in the lab," said Levy. "The mathematical model helps us understand the mechanisms that control the disease and show how to use this knowledge to our advantage."
University of Maryland
"By combining novel biological data and mathematical modeling, we found rules for designing adaptive treatments for each specific patient," said Levy, of the University of Maryland Center for Scientific Computation and Mathematical Modeling. "Give me a thousand patients and, with this mathematical model, I can give you a thousand different customized treatment plans."
Math and Leukemia
While the marriage of math and biology is only beginning to catch on in science, there have been other attempts to use equations to understand how leukemia develops and evolves over time. Levy, Lee, and Kim's study differed in that it took into account the patient's natural immune response in conjunction with the effects of imatinib, a drug that has been successful in putting CML patients into remission.
They wanted to see if they could develop a mathematical model, or set of rules, that would increase chances for long-term remission in individual patients. Over four years, Lee's laboratory collected data from CML patients, measuring the strength of each patient's immune response, in the form of the numbers and the activity of the anti-leukemia T cells, at different times during imatinib therapy.
"Our results suggest that it is not only the drug that sends the leukemia into remission, it's also the natural immune response," Levy said. "After starting imatinib, the anti-leukemia immune response gradually increases. However, it begins to weaken after it reaches a peak. This typically happens well into the treatment.
"Leukemia cells are still present, but in relatively low numbers that causes the immune response to wind down. Unfortunately, this is an ideal time for the cancer cells to develop drug resistance and render the therapy ineffective."
Best Time for Immune Response
Incorporating Lee's clinical data on immune response, Levy's model suggests that the immune response of the patients should be boosted at the time when their immune response starts weakening.
The authors suggest that such a stimulation can be provided in the form of "cancer vaccines," in which pre-therapy blood taken from patients is irradiated to kill active cancer cells, then introduced back to the patient. A strong stimulation of the immune system was shown to be active in vitro in Lee's lab experiments.
"The mathematical approach showed that it is imperative to connect the timing of the cancer vaccine with the individual profile of the immune response of each patient," Levy said. "The mathematical simulations suggest that a vaccine administered within the initial months of the treatment will have no effect on the progression of the disease. On the other hand, a well-timed vaccine can potentially cure the disease."
Individual Therapy Plan
But the dynamics of each patient's immune response differ. That's where the math comes in, says Levy. "We can find rules for application to a specific patient. We can measure each patient's parameters to find when the dosage will be most effective. Mathematics provides the tools that are necessary to tailor the treatment to the patient."
"While some parameters can be measured in the lab," said Levy. "The mathematical model helps us understand the mechanisms that control the disease and show how to use this knowledge to our advantage."
University of Maryland
Immune Response Current Events and Immune Response News RSSLung cancer cells activate inflammation to induce metastasis
A research team from the University of California, San Diego School of Medicine has identified a protein produced by cancerous lung epithelial cells that enhances metastasis by stimulating the activity of inflammatory cells.
Researchers engineer pancreatic cell transplants to evade immune response
In a finding that could significantly influence the way type 1 diabetes is treated, researchers at Albert Einstein College of Medicine of Yeshiva University have developed a technique for transplanting insulin-producing pancreatic cells that causes only a minimal immune response in recipients.
Scientists Identify New Congenital Neutropenia Syndrome and Causative Gene Mutation
A team of scientists has discovered a new syndrome associated with severe congenital neutropenia (SCN), a rare disorder in which children lack sufficient infection-fighting white cells, and identified the genetic cause of the syndrome: mutations in the gene Glucose-6-phosphatase, catalytic subunit 3 (G6PC3).
New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis.
Cancer drug effectively treats transplant rejections
University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.
May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?
While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations.
Researchers identify new anti-tumor gene
Researchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI that can interact with and suppress a key protein that is overexpressed in 90 percent of human cancers. The discovery could one day lead to an effective gene therapy for cancer.
Mathematical models of adaptive immunity
More than five million people die every year from infectious diseases, despite the availability of numerous antibiotics and vaccines.
Study first to show that RNA interference can facilitate vaccine development
Pharmaceutical companies and universities are racing to develop drugs that use the gene silencing mechanism known as RNA interference to treat a host of diseases.
Scans show immune cells intercepting parasites
Researchers may have identified one of the body's earliest responses to a group of parasites that causes illness in developing nations.
More Immune Response Current Events and Immune Response News Articles
 | Primer to The Immune Response by Tak W. Mak, Mary Saunders Primer to The Immune Response is an invaluable resource for college students, university undergraduates and students in medicine and other health professions who need a concise but complete and understandable introduction to immunology.This book is written in the same engaging conversational style as the published reference book The Immune Response: Basic and Clinical Principles and conveys the... |
 | Immunity: The Immune Response to Infectious and Inflammatory Disease (Primers in Biology) by Anthony DeFranco, Richard Locksley, Miranda Robertson An understanding of the immune system is central to the understanding of how the body interacts with its surroundings, and how it both protects itself and responds to infectious disease. But what processes underpin the body's response to infection? How does our immune system remember its previous encounters? And what happens when the tight regulation of the immune system fails? Immunity:... |
 | Five Star Science Fiction/Fantasy - Immune Response by Steve Perry A New York Times Bestselling Author In the deep woods of the Pacific Northwest, things aren't quite what they seem . . . Physician's Assistant Rick Scales has a quiet practice at the end of the road, near the Makah Indian Reservation, in Neah Bay, Washington. But amidst the Douglas fir along Puget Sound, Scales has come across a problem: his patients aren't dying the way they should. When a... |
 | Immune Response in the Criticaly Ill (Update in Intensive Care and Emergency Medicine) This book brings together basic scientists or clinicians from a variety of different backgrounds - immunology, infectious diseases or critical care - who share a common interest in understanding the changes that occur in immune responses in sepsis. It provides an up to date and unrivalled synthesis of current research in this rapidly developing... |
 | The Innate Immune Response to Infection |
| Regulation of the Immune Response | |
| Cancer Surveys Volume 22 Molecular Mechanisms of the Immune Response by W.F. and M.J. Owen editors Bodmer | |
| Local Immune Responses of the Gut by Newby/StokeS | |
| Molecular Aspects of Immune Response and Infectious Diseases (Advances in Host Defense Mechanisms) by H. Kiyono, E. Jirillo, C. Desimone | |
 | West Nile Encephalitis Virus Infection: Viral Pathogenesis and the Host Immune Response (Emerging Infectious Diseases of the 21st Century) West Nile virus is a neurotropic flavivirus that has emerged globally as a significant cause of viral encephalitis in humans. Infection of humans is associated with a febrile illness that can progress to meningitis and encephalitis with symptoms including cognitive dysfunction and flaccid paralysis. Following its introduction to the United States in 1999, West Nile virus rapidly disseminated... |
| © 2009 BrightSurf.com |